Arcellx, Inc.

ACLX

Arcellx, Inc.

ACLX

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-02-27Shares Purchased (TTM):0Shares Sold (TTM):186,831

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:51,505,365Shares Outstanding:56,305,535Institutional Ownership Pct.:91.47%

Earnings Market Reaction:

Filing Date:2026-02-26Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Assets
Cash And Cash Equivalents At Carrying Value	80	79	62	81	106	162	100	155	395	126	304	275
Marketable Securities Current	370	382	391	462	482	412	417	419	307	314	203	259
Assets Current
Assets Current	462	472	464	554	599	587	530	589	716	491	558	571
Due From Related Parties Current	-	-	-	-	-	-	-	-	-	-	29	21
Restricted Cash Current	0	0	0	0	0	0	0	0	2	-	-	-
Prepaid Expense And Other Assets Current	12	11	11	11	12	13	13	15	12	20	22	17
Restricted Cash Noncurrent	3	3	2	2	2	2	2	2	2	5	3	3
Marketable Securities Noncurrent	70	115	85	22	38	102	130	117	27	43	-	-
Property Plant And Equipment Net	43	43	44	46	46	47	46	45	43	38	22	14
Operating Lease Right Of Use Asset	24	23	23	24	24	24	24	24	27	29	29	30
Prepaid Expense Other Noncurrent	3	0	0	0	1	1	1	2	9	8	11	5
Assets	604	656	619	648	711	765	734	780	825	614	624	623
Liabilities And Stockhold…
Accounts Payable Current	6	4	2	4	2	6	5	3	3	7	6	5
Accrued Liabilities Current	35	47	53	43	57	43	42	34	18	17	12	14
Operating Lease Liability Current	8	7	7	7	7	7	7	7	8	7	6	5
Liabilities Current
Liabilities Current	104	118	122	112	125	137	88	108	118	173	156	166
Finance Lease Liability Current	0	0	0	0	0	11	19	33	39	48	38	35
Contract With Customer Liability Current	56	60	59	57	59	70	15	31	51	94	94	107
Operating Lease Liability Noncurrent	44	44	45	46	47	47	48	48	51	48	41	32
Finance Lease Liability Noncurrent	-	-	-	-	-	-	-	-	-	6	9	15
Contract With Customer Liability Noncurrent	53	52	60	69	76	83	96	112	171	121	124	106
Other Liabilities Noncurrent	0	0	0	3	9	15	15	15	-	-	-	-
Liabilities	202	215	227	231	257	282	247	283	340	348	330	319
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,127	1,108	1,004	975	951	931	912	894	874	675	664	650
Stockholders Equity
Accumulated Other Comprehensive Income Loss Net Of…	1	1	0	1	1	2	-1	-1	1	-0	-0	0
Stockholders Equity	402	441	392	417	455	483	487	497	485	266	294	304
Temporary Equity Carrying…
Retained Earnings Accumulated Deficit	-726	-668	-612	-559	-497	-450	-424	-397	-389	-409	-370	-346
Liabilities And Stockholders Equity	604	656	619	648	711	765	734	780	825	614	624	623
Preferred Stock Par Or Stated Value Per Share	0	-	-	0	0	-	-	-	-	0.001	0.001	0.001
Preferred Stock Shares Authorized	200	-	-	200	200	-	-	-	-	200	200	200
Preferred Stock Shares Issued	-	-	-	-	-	-	-	-	-	0	0	0
Preferred Stock Shares Outstanding	0	-	-	0	0	-	-	-	-	0	0	0
Common Stock Par Or Stated Value Per Share	0	0.001	0.001	0.001	0	0.001	0.001	0.001	0	0.001	0.001	0.001
Common Stock Shares Authorized	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000
Common Stock Shares Issued	58	58	55	55	54	54	54	53	52	49	48	48
Shares Outstanding	58	58	55	55	54	54	54	53	52	49	48	48

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2025	10.31%	16.16%	26.75%	-2.47%	12.09%	19.02%	-16.91%	-24.91%	-22.64%	0.78%	1.03%	-
2024	-1.38%	4.67%	22.15%	30.73%	57.40%	60.35%	-11.18%	-20.25%	-36.47%	12.93%	1.03%	-4.25%
2023	-2.87%	-26.86%	-22.88%	4.25%	7.39%	32.51%	23.56%	13.96%	39.65%	4.32%	-23.28%	-20.35%
2022	-	-	-	-	-	-	-	-	-	27.24%	33.19%	15.15%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Liquidity Ratios
Current Ratio	4.44	3.99	3.81	4.93	4.78	4.29	6.01	5.46	6.06	2.84	3.57	3.44
Quick Ratio	4.32	3.90	3.72	4.83	4.69	4.19	5.85	5.32	5.95	2.72	3.43	3.34
Working Capital	357.98M	353.69M	342.05M	441.69M	473.91M	450.28M	441.91M	480.83M	598.13M	318.31M	401.96M	405.31M
Leverage & Debt
Debt to Equity	0.50	0.49	0.58	0.55	0.56	0.58	0.51	0.57	0.70	1.31	1.12	1.05
Interest Coverage TTM	-	-	-	-	-	-	-	-	-	-	-325.87	-328.78
Debt Ratio	0.33	0.33	0.37	0.36	0.36	0.37	0.34	0.36	0.41	0.57	0.53	0.51
Efficiency & Turnover
Asset Turnover TTM	0.03	0.05	0.08	0.11	0.14	0.23	0.21	0.19	0.19	0.10	0.06	0.04
Per Share Metrics
Diluted EPS TTM	-4.07	-3.85	-3.34	-2.94	-2.00	-0.75	-1.01	-0.96	-1.47	-2.68	-3.81	-4.06
Free Cash Flow Per Share TTM	-3.78	-3.56	-2.19	-2.22	-1.81	0.07	-0.80	-0.63	3.87	2.16	2.19	2.41
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-1,135.61%	-675.67%	-376.26%	-248.22%	-127.46%	-44.55%	-55.73%	-57.14%	-81.47%	-307.14%	-601.90%	-1,092.14%
Net Profit Margin TTM	-1,027.25%	-607.01%	-329.93%	-211.46%	-99.46%	-25.94%	-37.23%	-38.39%	-64.08%	-274.59%	-568.27%	-1,060.64%
Growth Metrics
Net Revenue Growth (1Y)	-79.35%	-76.96%	-60.63%	-41.66%	-2.16%	230.33%	349.32%	635.05%	-	-	-	-
Net Income Growth (1Y)	113.26%	439.06%	248.83%	221.34%	51.86%	-68.79%	-70.56%	-73.40%	-62.53%	-	-	-
EPS Growth (1Y)	102.89%	412.71%	232.05%	206.81%	36.25%	-71.97%	-73.54%	-76.42%	-71.66%	-	-	-
Calculated Values
Free Cash Flow TTM	-212.59M	-201.18M	-123.24M	-122.49M	-96.90M	3.58M	-42.88M	-33.26M	186.15M	104.39M	105.39M	112.54M
Net Debt	-82.88M	-81.62M	-64.75M	-83.49M	-108.08M	-153.61M	-83.43M	-124.67M	-359.62M	-77.01M	-259.28M	-226.69M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-02-27Sale

Owner: Elghandour, Rami

Title: SEE REMARKS

Shares: 89,916

Price/Share: $113.92

Value: $10,243,230.72

Shares Owned: 276,051

Relationship: Director,Officer

Ownership: Direct

2026-02-25Sale

Owner: Gilson, Michelle

Title: CHIEF FINANCIAL OFFICER

Shares: 11,219

Price/Share: $113.82

Value: $1,276,946.58

Shares Owned: 33,938

Relationship: Officer

Ownership: Direct

2026-02-19Sale

Owner: Gilson, Michelle

Title: CHIEF FINANCIAL OFFICER

Shares: 8,384

Price/Share: $68.56

Value: $574,807.04

Shares Owned: 45,157

Relationship: Officer

Ownership: Direct

2026-02-17Sale

Owner: Gilson, Michelle

Title: CHIEF FINANCIAL OFFICER

Shares: 11,291

Price/Share: $69.61

Value: $785,966.51

Shares Owned: 53,541

Relationship: Officer

Ownership: Direct

2026-01-20Sale

Owner: Lubner, David Charles

Title: -

Shares: 6,000

Price/Share: $75.00

Value: $450,000.00

Shares Owned: 21,659

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-02-27	Elghandour, Rami	Director,Officer	SEE REMARKS	Direct	Sale	89,916	113.92	$10,243,230.72	276,051	4
2026-02-25	Gilson, Michelle	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	11,219	113.82	$1,276,946.58	33,938	4
2026-02-19	Gilson, Michelle	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	8,384	68.56	$574,807.04	45,157	4
2026-02-17	Gilson, Michelle	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	11,291	69.61	$785,966.51	53,541	4
2026-01-20	Lubner, David Charles	Director	-	Direct	Sale	6,000	75.00	$450,000.00	21,659	4
2026-01-14	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	5,882	68.51	$402,975.82	23,749	4
2026-01-13	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	7,437	65.51	$487,197.87	29,631	4
2026-01-12	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	6,131	64.15	$393,303.65	37,068	4
2025-11-17	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	340	90.00	$30,600.00	284	4
2025-10-15	Gilson, Michelle	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	5,364	91.04	$488,338.56	8,466	4
2025-10-06	Gilson, Michelle	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	1,064	86.22	$91,738.08	13,830	4
2025-09-30	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	21,034	81.40	$1,712,167.60	624	4
2025-09-29	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	73	80.16	$5,851.68	21,658	4
2025-09-26	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	12,396	80.12	$993,167.52	21,731	4
2025-09-19	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	300	80.00	$24,000.00	34,127	4
2025-06-10	Patel, Kavita	Director	-	Direct	Sale	1,500	67.36	$101,040.00	0	4
2025-05-27	Gilson, Michelle	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	12,235	64.00	$783,040.00	19,776	4
2025-05-20	Patel, Kavita	Director	-	Direct	Sale	1,500	58.43	$87,645.00	0	4
2025-04-29	Patel, Kavita	Director	-	Direct	Sale	1,500	64.20	$96,300.00	0	4
2025-04-08	Patel, Kavita	Director	-	Direct	Sale	1,500	57.50	$86,250.00	0	4
2025-03-18	Patel, Kavita	Director	-	Direct	Sale	1,500	71.64	$107,460.00	0	4
2025-02-26	Elghandour, Rami	Director,Officer	SEE REMARKS	Direct	Sale	38,300	61.93	$2,371,919.00	149,186	4
2025-02-25	Patel, Kavita	Director	-	Direct	Sale	1,500	63.16	$94,740.00	0	4
2025-02-24	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	10,155	64.09	$650,833.95	37,486	4
2025-02-04	Patel, Kavita	Director	-	Direct	Sale	1,500	64.57	$96,855.00	0	4
2025-01-14	Patel, Kavita	Director	-	Direct	Sale	1,500	66.30	$99,450.00	0	4
2025-01-08	Gilson, Michelle	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	3,997	73.69	$294,538.93	9,582	4
2025-01-08	Elghandour, Rami	Director,Officer	SEE REMARKS	Direct	Sale	13,837	73.69	$1,019,648.53	117,275	4
2025-01-08	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	3,553	73.69	$261,820.57	25,085	4
2025-01-06	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,975	77.17	$229,580.75	32,868	4/A
2025-01-06	Elghandour, Rami	Director,Officer	SEE REMARKS	Direct	Sale	15,111	77.17	$1,166,115.87	147,586	4/A
2025-01-06	Gilson, Michelle	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	5,621	77.17	$433,772.57	27,591	4/A
2024-12-24	Patel, Kavita	Director	-	Direct	Sale	1,500	77.26	$115,890.00	0	4
2024-12-03	Patel, Kavita	Director	-	Direct	Sale	1,500	92.02	$138,030.00	0	4
2024-11-15	Gilson, Michelle	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	1,761	90.93	$160,127.73	0	4
2024-11-12	Patel, Kavita	Director	-	Direct	Sale	1,500	106.33	$159,495.00	0	4
2024-11-11	Patel, Kavita	Director	-	Direct	Sale	15,238	106.30	$1,619,799.40	0	4
2024-11-08	Gilson, Michelle	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	12,354	101.29	$1,251,336.66	1,761	4
2024-10-22	Patel, Kavita	Director	-	Direct	Sale	1,500	89.69	$134,535.00	0	4
2024-10-01	Patel, Kavita	Director	-	Direct	Sale	1,500	82.24	$123,360.00	0	4
2024-09-17	Gilson, Michelle	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	15,000	77.69	$1,165,350.00	6,915	4
2024-09-10	Patel, Kavita	Director	-	Direct	Sale	1,500	74.41	$111,615.00	0	4
2024-09-05	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	3,421	70.02	$239,538.42	9,278	4
2024-09-03	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	27,451	68.09	$1,869,138.59	9,278	4
2024-08-26	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	21,684	70.97	$1,538,913.48	9,278	4
2024-08-20	Patel, Kavita	Director	-	Direct	Sale	1,500	65.88	$98,820.00	0	4
2024-08-16	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	5,450	65.05	$354,522.50	9,278	4
2024-08-01	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	20,000	60.76	$1,215,200.00	9,278	4
2024-07-30	Patel, Kavita	Director	-	Direct	Sale	1,500	62.38	$93,570.00	0	4
2024-07-16	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	10,901	65.30	$711,835.30	9,278	4
2024-07-12	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	1,780	60.21	$107,173.80	9,278	4
2024-07-09	Patel, Kavita	Director	-	Direct	Sale	1,500	56.69	$85,035.00	0	4
2024-07-01	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	20,000	55.73	$1,114,600.00	9,278	4
2024-06-27	Patel, Kavita	Director	-	Direct	Sale	10,000	54.26	$542,600.00	0	4
2024-06-26	Gilson, Michelle	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	12,877	53.96	$694,842.92	6,915	4
2024-06-12	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	20,000	55.58	$1,111,600.00	9,278	4
2024-05-24	Gilson, Michelle	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	12,121	50.71	$614,655.91	19,792	4
2024-05-01	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	18,168	52.16	$947,642.88	8,938	4
2024-04-16	Ware, Olivia C	Director	-	Direct	Sale	9,402	55.70	$523,691.40	0	4
2024-04-01	Elghandour, Rami	Director,Officer	SEE REMARKS	Direct	Sale	23,086	67.56	$1,559,690.16	69,253	4
2024-03-26	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	5,450	69.37	$378,066.50	8,938	4
2024-03-21	Carroll, Jill	Director	-	Indirect	Sale	504,263	70.55	$35,575,754.65	1,479,148	4
2024-03-18	Gilson, Michelle	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	6,825	69.38	$473,518.50	9,485	4
2024-03-15	Ware, Olivia C	Director	-	Direct	Sale	9,000	70.26	$632,340.00	0	4
2024-02-12	Heery, Christopher	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	2,967	64.46	$191,252.82	30,303	4
2024-02-12	Elghandour, Rami	Director,Officer	SEE REMARKS	Direct	Sale	11,169	64.46	$719,953.74	92,339	4
2024-01-04	Gilson, Michelle	Officer	Chief Financial Officer	Direct	Sale	8,514	55.27	$470,568.78	16,310	4
2024-01-04	Elghandour, Rami	Director,Officer	See Remarks	Direct	Sale	29,073	55.27	$1,606,864.71	60,193	4
2024-01-04	Heery, Christopher	Officer	Chief Medical Officer	Direct	Sale	7,598	55.27	$419,941.46	17,859	4
2023-12-18	Heery, Christopher	Officer	Chief Medical Officer	Direct	Sale	120,000	50.98	$6,117,600.00	7,795	4
2023-12-14	Carroll, Jill	Director	-	Indirect	Sale	504,263	49.13	$24,774,441.19	1,983,411	4
2023-08-04	Heery, Christopher	Officer	Chief Medical Officer	Direct	Sale	3,000	35.38	$106,140.00	7,795	4
2023-07-03	Heery, Christopher	Officer	Chief Medical Officer	Direct	Sale	3,000	31.75	$95,250.00	7,795	4
2023-06-01	Carroll, Jill	Director	-	Indirect	Sale	25,556	44.35	$1,133,408.60	2,487,674	4
2023-05-31	Elghandour, Rami	Director,Officer	See Remarks	Direct	Sale	2,600	44.27	$115,102.00	36,169	4
2023-05-25	Gilson, Michelle	Officer	Chief Financial Officer	Direct	Sale	6,000	42.77	$256,620.00	9,485	4
2023-05-11	Carroll, Jill	Director	-	Indirect	Sale	638,417	45.58	$29,099,046.86	2,828,394	4
2023-05-11	Sr, One Capital Partners …	TenPercentOwner	-	Indirect	Sale	1,012,833	45.58	$46,164,928.14	1,658,780	4
2023-05-10	Heery, Christopher	Officer	Chief Medical Officer	Direct	Sale	2,197	45.18	$99,260.46	7,795	4
2023-05-05	Heery, Christopher	Officer	Chief Medical Officer	Direct	Sale	1,200	45.00	$54,000.00	10,492	4
2023-05-03	Heery, Christopher	Officer	Chief Medical Officer	Direct	Sale	3,000	43.14	$129,420.00	11,692	4
2023-04-24	Heery, Christopher	Officer	Chief Medical Officer	Direct	Sale	20,000	40.00	$800,000.00	11,692	4
2023-04-19	Heery, Christopher	Officer	Chief Medical Officer	Direct	Sale	15,642	35.01	$547,626.42	11,692	4
2023-04-03	Heery, Christopher	Officer	Chief Medical Officer	Direct	Sale	3,000	30.90	$92,700.00	15,589	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

91.47%

Inst. Shares: 51,505,365

Shares Outstanding: 56,305,535

2025-12-31

95.68%

Inst. Shares: 53,873,817

Shares Outstanding: 56,305,535

2025-09-30

97.09%

Inst. Shares: 54,938,464

Shares Outstanding: 56,587,167

2025-06-30

102.11%

Inst. Shares: 57,408,902

Shares Outstanding: 56,221,331

2025-03-31

103.59%

Inst. Shares: 57,237,627

Shares Outstanding: 55,256,464

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	51,505,365	56,305,535	91.47%
2025-12-31	53,873,817	56,305,535	95.68%
2025-09-30	54,938,464	56,587,167	97.09%
2025-06-30	57,408,902	56,221,331	102.11%
2025-03-31	57,237,627	55,256,464	103.59%
2024-12-31	53,953,762	53,566,153	100.72%
2024-09-30	45,424,274	53,821,893	84.40%
2024-06-30	46,247,779	53,516,907	86.42%
2024-03-31	43,133,720	52,757,973	81.76%
2023-12-31	43,009,401	48,061,450	89.49%
2023-09-30	44,265,713	48,348,094	91.56%
2023-06-30	45,311,849	48,106,528	94.19%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Arcellx, Inc. (ACLX) — SEC Financial Statements & Analysis

Arcellx, Inc. (ACLX) is a biological products, (no diagnostic substances) company, incorporated in DE. Arcellx, Inc. trades on Nasdaq as: ACLX. Based on its latest SEC filing (Form 10-Q, period ending 2025-12-31), Arcellx, Inc. reported a -79.35% year-over-year revenue growth, a Debt-to-Equity ratio of 0.50x. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -79.35%
Debt To Equity: 0.50x

Data as of 2025-12-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Arcellx, Inc. in?

Arcellx, Inc. (ACLX) operates in the Biological Products, (No Diagnostic Substances) industry.

What exchange does ACLX trade on?

Arcellx, Inc. (ACLX) trades on the Nasdaq.

Where is Arcellx, Inc. incorporated?

Arcellx, Inc. is incorporated in DE.

Arcellx, Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

Arcellx, Inc. (ACLX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.
Main Street's price.

Arcellx, Inc. (ACLX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.